Zinplava (Bezlotoxumab Vials) 25 mg/mL-40ml

ZINPLAVA (bezlotoxumab) is an intravenous therapy used to reduce recurrence of Clostridium difficile infection in adults. This monoclonal antibody targets C. difficile toxin B to support gut health recovery. Ideal for post-antibiotic care, it is administered in clinical settings. Short version: bezlotoxumab injection helps prevent recurrent C. difficile infection after antibiotic treatment.

Strength

25 mg/mL-40ml

Manufacturer / TM Owner

Merck Sharp & Dohme Corp.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Bezlotoxumab is used to lower the risk of Clostridium difficile infection returning in adults who have already completed antibiotic treatment for the infection. It works by binding to toxin B produced by C. difficile bacteria, helping the body clear the infection more effectively. This medication is typically given as a single dose in a healthcare setting to support recovery and reduce recurrence.

Side Effects

After receiving bezlotoxumab, some patients may experience mild infusion-related effects such as headache, nausea, or fatigue. These effects are usually temporary and resolve shortly after the infusion. The therapy is designed to support the body’s natural recovery process without causing direct symptom relief itself.

Precautions & Warnings

Bezlotoxumab should be handled and administered by healthcare professionals in a controlled environment. Patients with a history of heart failure should inform their provider, as the infusion may require careful monitoring. Ensure all pre-infusion screenings are completed to rule out active infections or allergies before receiving the dose.

Avoid Interactions

Bezlotoxumab is a monoclonal antibody and does not interact with most medications in the same way as small-molecule drugs. However, patients should disclose all current medications to their healthcare provider to rule out any potential immune-related concerns. No specific drug-drug interactions have been widely reported, but caution is advised with other immune-modulating therapies.

Frequently Asked Questions

Bezlotoxumab is used to reduce the risk of recurrent Clostridium difficile infection in adults after completing antibiotic treatment.

It is given as a single intravenous infusion in a healthcare setting, typically over 60 minutes.

Yes, it is designed to be used after completing a course of antibiotics for C. difficile infection.

Common effects may include headache, nausea, or fatigue, which are usually mild and temporary.

It should be used under medical supervision; patients with heart failure history may require monitoring during infusion.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.